699852P

3D-PHAD^™

Avanti Research^™ - A Croda Brand

• Synonym(s): Monophosphoryl 3-Deacyl Lipid A (Synthetic) Pat No. 9,241,988
• Empirical Formula (Hill Notation): C₈₂H₁₅₈N₃O₂₀P
• CAS Number: 1699735-79-9
• Molecular Weight: 1537.11
• UNSPSC Code: 12352211
• NACRES: NA.25

Properties

• Assay: >99% (HPLC)
• form: powder
• packaging: pkg of 1 × 1 mg (699852P-1mg); pkg of 1 × 5 mg (699852P-5mg)
• manufacturer/tradename: Avanti Research^™ - A Croda Brand
• application(s): vaccine development
• shipped in: dry ice
• storage temp.: −20°C
• SMILES string: O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](O)[C@@H]2NC(C[C@H](O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]
• InChI: 1S/C82H155N2O20P.H3N/c1-6-11-16-21-26-31-33-38-43-48-53-58-72(89)99-66(56-51-46-41-36-29-24-19-14-9-4)61-71(88)84-76-80(103-74(91)62-67(57-52-47-42-37-30-25-20-15-10-5)100-73(90)59-54-49-44-39-34-32-27-22-17-12-7-2)79(104-105(95,96)97)68(63-85)102-82(76)9
• InChI key: XERJCJBCCDONJL-WOBTUNBLSA-N

Description

General description

Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD^™), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

Application

3D-PHAD^™ has been used:

• as a synthetic adjuvant for respiratory syncytial virus (RSV) vaccine
• as a synthetic adjuvant to prepare hepatitis B virus (HBV) and virus-like particles (VLP)-based human papillomavirus (HPV) vaccines
• in liposome preparation for the generation of army liposome formulation (ALF) for human immunodeficiency (HIV) gp140 antigen immunization studies in mice.

Biochem/physiol Actions

3-deacyl-phosphorylated hexa-acyl disaccharide (3D-PHAD^™) is derived from monophosphoryl lipid A. It is amphiphilic and associates with the virosomal membranes.

Features and Benefits

The highly pure MPLA analog, 3D-PHAD^™, provides a homogeneous synthetic equivalent for the 3-deacylated MPLA derived from bacterial LPS. 3D-PHAD^™ is less pyrogenic than its bacterial-derived mimic while eliciting a comparable response to other MPLA analogs.

Packaging

2 mL Amber Glass Crimp Cap Vial (699852P-1mg)

2 mL Amber Glass Crimp Cap Vial (699852P-5mg)

Other Notes

For R&D use only. Not for drug, household, or other uses.

Legal Information

3D-PHAD is a trademark of Avanti Polar Lipids, LLC

Avanti Research is a trademark of Avanti Polar Lipids, LLC

PHAD is a trademark of Avanti Polar Lipids, LLC

Safety Information

• Storage Class Code: 11 - Combustible Solids